尼妥珠单抗联合同步放化疗治疗鼻咽癌的效果及对血清肿瘤标志物的影响

Effects of Nimotuzumab Combined with Concurrent Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma and Its Impact on Serum Tumor Markers

目的:探讨给予鼻咽癌患者尼妥珠单抗联合同步放化疗的效果及对血清肿瘤标志物的影响。方法:选取2021年1月—2022年1月赣州市人民医院收治的鼻咽癌患者共计92例,以随机数字表法分成研究组(46例)与对照组(46例),对照组给予同步放化疗治疗,研究组给予尼妥珠单抗联合同步放化疗治疗,比较两组近期疗效、血清肿瘤标志物、氧化应激指标及不良反应。结果:研究组客观缓解率(ORR)、疾病控制率(DCR)均较对照组高,差异均有统计学意义(P<0.05);两组治疗后细胞角蛋白19片段(CYFRA21-1)、鳞状细胞癌相关抗原(SCCAg)水平均降低,研究组均较对照组低,差异均有统计学意义(P<0.05);两组治疗后丙二醛(MDA)、一氧化氮(NO)水平均升高,超氧化物歧化酶(SOD)水平均降低,但研究组MDA、NO水平均较对照组低,SOD水平较对照组高,差异均有统计学意义(P<0.05);研究组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论:给予鼻咽癌患者尼妥珠单抗联合同步放化疗,能够提高近期疗效,调节血清肿瘤标志物、氧化应激指标水平,不良反应较小。

Objective:To explore the effect of Nimotuzumab combined with concurrent radiotherapy and chemotherapy in nasopharyngeal carcinoma patients and its impact on serum tumor markers.Method:A total of 92 patients with nasopharyngeal carcinoma admitted to Ganzhou People's Hospital from January 2021 to January 2022 were selected and divided into the study group(46 cases)and the control group(46 cases)by the random number table method.The control group was treated with concurrent radiotherapy and chemotherapy,and the study group was treated with Nimotuzumab combined with concurrent radiotherapy and chemotherapy.The shortterm efficacy,serum tumor markers,oxidative stress indexes and adverse reactions were compared between the two groups.Result:The objective response rate(ORR)and disease control rate(DCR)in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of cytokeratin 19 fragment(CYFRA21-1)and squamous cell carcinoma associated antigen(SCCAg)in the two groups were decreased,and those in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of malondialdehyde(MDA)and nitric oxide(NO)in the two groups increased,and the levels of superoxide dismutase(SOD)decreased,but the levels of MDA and NO in the study group were lower than those in the control group,and the level of SOD in the study group was higher than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion:The combination of Nimotuzumab and concurrent radiotherapy and chemotherapy for nasopharyngeal carcinoma patients can improve short-term efficacy,regulate serum tumor markers and oxidative stress indicators levels,and have fewer adverse reactions.